Lachesis Biosciences ASX Initial Public Offer - Prospectus and Application
Lachesis Biosciences ASX Initial Public Offer - Prospectus and Application
Sydney, Sep 15, 2016 AEST (ABN Newswire) - Lachesis Biosciences Limited are pleased to provide a Prospectus to raise up to $6,000,000 by an Offer to the public comprising: Offer of 5,000,000 New Shares at an issue price of $1.00 each totaling $5,000,000; and Oversubscriptions of up to a maximum of $1,000,000.

Nasal Drug Delivery for Neurodegenerative Diseases

Investment Overview

What is the industry in which Lachesis Biosciences operates?

Lachesis Biosciences operates in the field of research, development and commercialisation of prescription pharmaceutical products for human use in neurodegenerative disease conditions.

What is Lachesis Biosciences' business?

Lachesis Biosciences is a development company focused on nasal spray and nasal absorption technology. Lachesis Biosciences clinical-stage, Rivastigmine Nasal Spray product candidate is for the treatment of dementia symptoms associated with Alzheimer's and Parkinson's diseases.

Rationale for development of Rivastigmine Nasal Spray

Rivastigmine was originally developed by Novartis and approved in 1997 to treat mild to moderate Alzheimer's Disease (AD) dementia, and is available in over 90 countries in oral and transdermal patch form.

Drugs such as rivastigmine are one of a handful of drug classes that are used to treat diseases or disorders of the human central nervous system. The Directors believe that rivastigmine has the potential to be reformulated into a nasal spray to overcome the problems associated with current rivastigmine delivery methods, including tolerability problems (gastrointestinal side effects and sleeplessness), together with the convenience of adjustable, individual dosing during waking hours.

Does Lachesis Biosciences have any patents over its intellectual property?

Lachesis Biosciences has a patent pending for its nasal spray technology, compositions and methods.

How does Lachesis Biosciences intend to generate its income?

By either partnering (licensing) its pipeline products with larger pharmaceutical companies, or manufacturing and promoting its pipeline products to medical specialists using its own prospective commercial capability.

Why is the Offer being conducted?

To further the development of its product pipeline, in particular Rivastigmine Nasal Spray

Listen to an Investor Presentation with CEO and Managing Director, Tim Morgan, with Boardroom Media:
http://www.abnnewswire.net/lnk/L1HO9777

Visit the latest Lachesis Biosciences' News at:
http://www.lachesisbiosciences.com/news.html

Existing nasal spray devices reliably deliver our proprietary formulations to the inferior (lower) nasal turbinate where they penetrate across the nasal mucosa and into the bloodstream, bypassing the gut and liver.

We apply our technology to drugs that need further improvement in terms of their clinical effect, tolerability and convenience.

Rivastigmine Nasal Spray

Using our lead product as an example, the delivery of rivastigmine using nasal absorption was more efficient than the transdermal patch and oral capsule because the absolute bioavailability (F %) in elderly individuals was higher. This also helps lower the cost of goods of the product.

Nasal Absorption

Key Investment Highlights

- High unmet need in the Alzheimer's disease (AD) dementia market:

-- Strong need for improved therapies

-- Rapidly growing market

--- ~10M new AD dementia cases diagnosed WW each year

--- Market growth from aging population and increased diagnosis

- Clinical, regulatory and manufacturing proof of concept completed

- Lower risk development pathway to market

- Reduced timeframe and expenditure to revenues

- Experienced team

-- Track record of new product approvals, licensing and commercialisation

To view the Lachesis IPO Information & Prospectus, please visit:
http://www.abnnewswire.net/lnk/02070Z45

Nasal Absorption

Existing nasal spray devices reliably deliver our proprietary formulations to the inferior (lower) nasal turbinate where they penetrate across the nasal mucosa and into the bloodstream, bypassing the gut and liver.

We apply our technology to drugs that need further improvement in terms of their clinical effect, tolerability and convenience.

Rivastigmine Nasal Spray

Using our lead product as an example, the delivery of rivastigmine using nasal absorption was more efficient than the transdermal patch and oral capsule because the absolute bioavailability (F %) in elderly individuals was higher. This also helps lower the cost of goods of the product.

For more information, please visit:
http://www.boardroom.services/lachesis-biosciences

To download the Prospectus, please visit:
http://abnnewswire.net/lnk/XQFQ648P


About Lachesis Biosciences

Lachesis Biosciences Lachesis Biosciences is a development company focused on nasal spray and nasal absorption technology. Lachesis Biosciences clinical-stage, Rivastigmine Nasal Spray product candidate is for the treatment of dementia symptoms associated with Alzheimer’s and Parkinson’s diseases.

 


Contact

Business Development
T: +61-3-5561-7758
E: partnering@lachesisbio.com.au



Related Companies

Lachesis Biosciences
Boardroom Media

ABN Newswire This Page Viewed:  (Last 7 Days: 5) (Last 30 Days: 63) (Since Published: 3570) 
ANALYTICS: LOGIN HERE

Lachesis Biosciences NEWS: RECENT VISITS (63)